| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 16.05.
| Ablynx: ABLYNX ANNOUNCES Q1 2012 BUSINESS UPDATE | | 24 | Thomson Reuters ONE |
| REGULATED INFORMATION GHENT, Belgium, 16th May 2012 - Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the...
Mehr lesen zu:
Ablynx: ABLYNX ANNOUNCES Q1 2012 BUSINESS UPDATE | |
| 27.04.
| Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") | | 44 | Thomson Reuters ONE |
| REGULATED INFORMATION GHENT, Belgium, 27 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of...
Mehr lesen zu:
Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") | |
| 25.04.
| Ablynx: NANOBODY FOR ALZHEIMER'S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS PHASE I CLINICAL TRIALS | | 71 | Thomson Reuters ONE |
| - Ablynx to receive €1 million milestone payment - GHENT, Belgium, 25 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has submitted a Clinical Trials Application...
Mehr lesen zu:
Ablynx: NANOBODY FOR ALZHEIMER'S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS PHASE I CLINICAL TRIALS | |
| 04.04.
| Ablynx: ABLYNX'S PARTNER SHOWS THAT A NANOBODY CAN ELICIT SUPERIOR ANTI-TUMOUR EFFICACY COMPARED TO CONVENTIONAL MONOCLONAL ANTIBODY APPROACHES | | 76 | Thomson Reuters ONE |
| Pre-clinical data presented at AACR in Chicago GHENT, Belgium, 4 April 2012 - Ablynx [Euronext Brussels: ABLX] today noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting...
Mehr lesen zu:
Ablynx: ABLYNX'S PARTNER SHOWS THAT A NANOBODY CAN ELICIT SUPERIOR ANTI-TUMOUR EFFICACY COMPARED TO CONVENTIONAL MONOCLONAL ANTIBODY APPROACHES | |
| 02.04.
| Ablynx: ABLYNX RECEIVES MILESTONE PAYMENT AS COLLABORATOR RECEIVES IND APPROVAL FOR A NANOBODY IN ONCOLOGY | | 66 | Thomson Reuters ONE |
| GHENT, Belgium, 2 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by...
Mehr lesen zu:
Ablynx: ABLYNX RECEIVES MILESTONE PAYMENT AS COLLABORATOR RECEIVES IND APPROVAL FOR A NANOBODY IN ONCOLOGY | |
| 20.03.
| Ablynx: ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STR... | | 2 | InvestEgate |
| 20.03.
| Ablynx: ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STRATEGIC NANOBODY ALLIANCE WITH BOEHRINGER INGELHEIM | | 48 | Thomson Reuters ONE |
| GHENT, Belgium, 20 March 2012 - Ablynx [Euronext Brussels: ABLX] today announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic...
Mehr lesen zu:
Ablynx: ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STRATEGIC NANOBODY ALLIANCE WITH BOEHRINGER INGELHEIM | |
| 01.03.
| Ablynx: ABLYNX PRESENTS PIPELINE AND TECHNOLOGY UPDATE ... | | 4 | InvestEgate |
| 01.03.
| Ablynx: ABLYNX PRESENTS PIPELINE AND TECHNOLOGY UPDATE AT R&D DAY IN NEW YORK | | 60 | Thomson Reuters ONE |
| GHENT, Belgium, 1st March 2012 - Ablynx [Euronext Brussels: ABLX] will present recent developments and provide an outlook on its partnered and proprietary clinical and pre-clinical pipeline,...
Mehr lesen zu:
Ablynx: ABLYNX PRESENTS PIPELINE AND TECHNOLOGY UPDATE AT R&D DAY IN NEW YORK | |
| 22.02.
| Ablynx: ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS | | 3 | InvestEgate |
| 22.02.
| Ablynx: ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS | | 35 | Thomson Reuters ONE |
| REGULATED INFORMATION Strong year of progress at Ablynx as first Nanobody® reaches clinical proof-of-concept GHENT, Belgium, 22nd February 2012 - Ablynx (Euronext Brussels: ABLX), the Belgian-based...
Mehr lesen zu:
Ablynx: ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS | |
| 15.02.
| Ablynx: ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2011... | | 3 | InvestEgate |
| 15.02.
| Ablynx: ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2011 WITH WEBCAST | | 38 | Thomson Reuters ONE |
| GHENT, Belgium, 15 February 2012 - Ablynx [Euronext Brussels: ABLX] plans to announce its full year results for 2011 on 22 February 2012 after market closure. Dr Edwin Moses, CEO and Chairman of...
Mehr lesen zu:
Ablynx: ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2011 WITH WEBCAST | |
| 14.02.
| Ablynx: ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APP... | | 2 | InvestEgate |
| 14.02.
| Ablynx: ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR ANDREAS MENRAD AS CHIEF SCIENTIFIC OFFICER | | 55 | Thomson Reuters ONE |
| GHENT, Belgium, 14 February 2012 - Ablynx [Euronext Brussels: ABLX], today announced that it has appointed Dr Andreas Menrad as its Chief Scientific Officer. Dr Menrad has over 20 years experience...
Mehr lesen zu:
Ablynx: ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR ANDREAS MENRAD AS CHIEF SCIENTIFIC OFFICER | |
| 01.02.
| Ablynx: ABLYNX RECEIVES ANOTHER MILESTONE AS BOEHRINGER INGELHEIM SELECTS NANOBODY CANDIDATE FOR PRE-CLINICAL DEVELOPMENT | | 46 | Thomson Reuters ONE |
| GHENT, Belgium, 1 February 2012 - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical...
Mehr lesen zu:
Ablynx: ABLYNX RECEIVES ANOTHER MILESTONE AS BOEHRINGER INGELHEIM SELECTS NANOBODY CANDIDATE FOR PRE-CLINICAL DEVELOPMENT | |
| 22.01.
| Ablynx: ABLYNX STATEMENT ON PRESS ARTICLE AND RELATED SHARE PRICE MOVEMENTS | | 82 | Thomson Reuters ONE |
| GHENT, Belgium, 22 January 2012 - Ablynx [Euronext Brussels: ABLX] issued the following statement today. On Friday January 20th at 16.30 C.E.T., De Tijd, a Belgian newspaper, published online what...
Mehr lesen zu:
Ablynx: ABLYNX STATEMENT ON PRESS ARTICLE AND RELATED SHARE PRICE MOVEMENTS | |
| 10.01.
| Ablynx: ABLYNX IS GRANTED EXTENDED GMP CERTIFICATE FOR NEW GMP UNIT | | 34 | Thomson Reuters ONE |
| GHENT, Belgium, 10 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has been granted an extended Certificate of Good Manufacturing Practice (GMP) from the Federal Agency for Medicines...
Mehr lesen zu:
Ablynx: ABLYNX IS GRANTED EXTENDED GMP CERTIFICATE FOR NEW GMP UNIT | |
| 09.01.
| Ablynx: ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012 STRATEGY AT 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | | 39 | Thomson Reuters ONE |
| GHENT, Belgium, 9 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and...
Mehr lesen zu:
Ablynx: ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012 STRATEGY AT 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | |
| 04.01.
| Ablynx: ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | | 30 | Thomson Reuters ONE |
| GHENT, Belgium, 4 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it plans to webcast its corporate presentation at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday...
Mehr lesen zu:
Ablynx: ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | |
